2024-09-04 - Analysis Report
## REGN Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that develops and commercializes life-saving medicines for serious diseases. 

**Performance Analysis:**

1. **Relative Performance:**

   * **REGN's cumulative return:** 159.56%
   * **S&P 500 (VOO) cumulative return:** 89.66%
   * **REGN outperformance:** 69.9% (95.82% relative to historical range). 

   REGN has significantly outperformed the S&P 500 over the period considered, with a return more than 70% higher. Its relative performance is near the top of its historical range.

2. **Recent Price Movement:**

   * **Closing price:** 1184.69
   * **5-day moving average:** 1192.81
   * **20-day moving average:** 1158.3
   * **60-day moving average:** 1090.18

   The stock price is currently trading slightly below its 5-day moving average, indicating short-term downward pressure. However, it remains above both the 20-day and 60-day moving averages, suggesting a potential upward trend in the medium to long term.

3. **Technical Indicators:**

   * **RSI:** 73.51 (Overbought territory)
   * **PPO:** -0.17 (Weakly bearish)
   * **Delta_Previous_Relative_Divergence:** -4.18 (Short-term downward trend)
   * **Expected_Return:** 3.13% (5-year estimated return)

   The RSI indicates overbought conditions, implying potential for a short-term correction. The negative PPO suggests a weak bearish sentiment. The short-term relative divergence is also negative, confirming the potential for a pullback. However, the expected return remains positive, hinting at potential for long-term growth.

4. **Recent Earnings and Outlook:**

   | Date | EPS | Revenue |
   |---|---|---|
   | 2024-08-01 | 13.25 | 3.55 B$ |
   | 2024-05-02 | 6.7 | 3.15 B$ |
   | 2023-11-02 | 9.48 | 3.36 B$ |
   | 2023-08-03 | 9.05 | 3.16 B$ |
   | 2024-08-01 | 9.05 | 3.16 B$ |

   The most recent earnings report (2024-08-01) showed strong performance with EPS exceeding expectations. However, revenue came in slightly below expectations. Overall, REGN continues to demonstrate solid growth and profitability.

**Conclusion:**

REGN has exhibited strong performance with significant outperformance compared to the broader market. However, technical indicators suggest a potential for short-term correction due to overbought conditions and negative momentum. Despite the short-term headwinds, the long-term outlook remains positive, supported by solid earnings performance and continued growth potential. Investors should consider the current overbought situation and potential for short-term volatility before making any investment decisions. Long-term investors may consider holding their position with a focus on the company's strong fundamentals and long-term growth potential. 
